Vas Narasimhan wants Novartis to have a big focus on China. Here’s what that looks like
As China secures a spot in every multinational pharma giant CEO’s mind with its enormous market and rapid regulatory reforms, Novartis’ Vas Narasimhan is ready to set clear goals
Briefing investors on an earnings call, Narasimhan mapped out one of the most detailed cases for ramping up sales of new drugs in China. Reiterating a goal to score 50 NDA approvals between 2020 and 2024, he notes:
That’s a doubling of the rate we’ve had over recent years, and our goal is to deliver greater than 90% of our 2024 and beyond China submissions simultaneously with global submissions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.